Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters

[1]  N. Bornfeld,et al.  Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma , 2010, British Journal of Ophthalmology.

[2]  R. Xiang,et al.  Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model , 2009, PloS one.

[3]  J. Becker,et al.  Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. , 2009, The Journal of clinical investigation.

[4]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[5]  J. Buchner,et al.  The Hsp90 Chaperone Machinery* , 2008, Journal of Biological Chemistry.

[6]  D. Faingold,et al.  Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma , 2008, Clinical Cancer Research.

[7]  A. Józkowicz,et al.  Heme oxygenase-1 in tumors: is it a false friend? , 2007, Antioxidants & redox signaling.

[8]  H. Maeda,et al.  Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. , 2007, Blood.

[9]  L. Neckers,et al.  Heat shock protein 90: The cancer chaperone , 2007, Journal of Biosciences.

[10]  Yuval Kluger,et al.  High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.

[11]  J. Léger,et al.  Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. , 2006, The American journal of pathology.

[12]  F. Garbagnati,et al.  HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. , 2006, Anticancer research.

[13]  D. Sawyer,et al.  Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.

[14]  N. Rosen,et al.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[16]  A. Benner,et al.  Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases. , 2004, International Journal of Oncology.

[17]  W. Stolz,et al.  Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases , 2004, Experimental dermatology.

[18]  J. Keunen,et al.  Heat shock protein expression in the eye and in uveal melanoma. , 2003, Investigative ophthalmology & visual science.

[19]  M. Landthaler,et al.  Heat shock protein 70 membrane expression and melanoma‐associated marker phenotype in primary and metastatic melanoma , 2003, Melanoma research.

[20]  B. Stewart,et al.  World Cancer Report , 2003 .

[21]  Peter J. S. Hutzler,et al.  Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells1 , 2002, The Journal of Immunology.

[22]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Karakousis,et al.  Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  S. Murphy,et al.  Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. , 1999, Human gene therapy.

[25]  H. Band,et al.  Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. , 1998, International immunology.

[26]  P. T. Thomas,et al.  Heat shock protein expression in fish , 1998, Reviews in Fish Biology and Fisheries.

[27]  H. Band,et al.  Restoration of MHC Class I Surface Expression and Endogenous Antigen Presentation by a Molecular Chaperone , 1997, Scandinavian journal of immunology.

[28]  R. Issels,et al.  Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. , 1997, Journal of immunology.

[29]  M. Maines,et al.  Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. , 1996, Urology.

[30]  D R Ciocca,et al.  Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. , 1993, Journal of the National Cancer Institute.

[31]  M J Schlesinger,et al.  Heat shock proteins. , 1990, The Journal of biological chemistry.

[32]  M. Jäättelä,et al.  Heat shock protects WEHI‐164 target cells from the cytolysis by tumor necrosis factors α and β , 1989 .

[33]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[34]  Y. Kluger,et al.  HSP90 as a marker of progression in melanoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  H. Dihazi,et al.  T cell epitope definition by differential mass spectrometry: Identification of a novel, immunogenic HLA‐B8 ligand directly from renal cancer tissue , 2006, Proteomics.

[36]  A. McMichael,et al.  Solar Ultraviolet Radiation: Global burden of disease from solar ultraviolet radiation , 2006 .

[37]  Stuart K. Calderwood,et al.  Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications , 2005, Cell stress & chaperones.

[38]  A. Lazaris,et al.  Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma , 2004, Virchows Archiv.

[39]  K. Busam,et al.  Melan-A, a new melanocytic differentiation marker. , 1999, Advances in anatomic pathology.

[40]  G. Kimura,et al.  Heat shock proteins and the antitumor T cell response , 1998, Biotherapy.

[41]  M. Jäättelä,et al.  Heat shock protects WEHI-164 target cells from the cytolysis by tumor necrosis factors alpha and beta. , 1989, European Journal of Immunology.